Abstract:Summary Background Accurate tumour response prediction to targeted therapy allows for personalised conversion therapy for patients with unresectable colorectal cancer liver metastases (CRLM). In this study, we aimed to develop and validate a multi-modal deep learning model to predict the efficacy of bevacizumab in patients with initially unresectable CRLM using baseline PET/CT, clinical data, and colonoscopy biopsy specimens. Methods In this multicentre cohort study, we retrospectively collected data of 307 patients with CRLM from the BECOME study ( NCT01972490 ) (Zhongshan Hospital of Fudan University, Shanghai) and two independent Chinese cohorts (internal validation cohort from January 1, 2018 to December 31, 2018 at Zhongshan Hospital of Fudan University; external validation cohort from January 1, 2020 to December 31, 2020 at Zhongshan Hospital—Xiamen, Shanghai, and the First Hospital of Wenzhou Medical University, Wenzhou). The main inclusion criteria were that patients with CRLM had pre-treatment PET/CT images as well as colonoscopy specimens. After extracting PET/CT features with deep neural networks (DNN) and selecting related clinical factors using LASSO analysis, a random forest classifier was built as the Deep Radiomics Bevacizumab efficacy predicting model (DERBY). Furthermore, by combining histopathological biomarkers into DERBY, we established DERBY + . The performance of model was evaluated using area under the curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value. Findings DERBY achieved promising performance in predicting bevacizumab sensitivity with an AUC of 0.77 and 95% confidence interval (CI) [0.67–0.87]. After combining histopathological features, we developed DERBY + , which had more robust accuracy for predicting tumour response in external validation cohort (AUC 0.83 and 95% CI [0.75–0.92], sensitivity 80.4%, specificity 76.8%). DERBY + also had prognostic value: the responders had longer progression-free survival (median progression-free survival: 9.6 vs 6.3 months, p = 0.002) and overall survival (median overall survival: 27.6 vs 18.5 months, p = 0.010) than non-responders. Interpretation This multi-modal deep radiomics model, using PET/CT, clinical data and histopathological data, was able to identify patients with bevacizumab-sensitive CRLM, providing a favourable approach for precise patient treatment. To further validate and explore the clinical impact of this work, future prospective studies with larger patient cohorts are warranted. Funding The National Natural Science Foundation of China ; Fujian Provincial Health Commission Project ; Xiamen Science and Technology Agency Program ; Clinical Research Plan of SHDC ; Shanghai Science and Technology Committee Project ; Clinical Research Plan of SHDC ; Zhejiang Provincial Natural Science Foundation of China ; and National Science Foundation of Xiamen .

Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab

A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer

Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients

Total and Not Bevacizumab-Bound Vascular Endothelial Growth Factor As Potential Predictive Factors to Bevacizumab-Based Chemotherapy in Colorectal Cancer.

Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer using a multi-marker panel and a machine-learning approach: Final results of the prospective multicenter PERMAD trial.

Machine Learning-Based LIBS Spectrum Analysis of Human Blood Plasma Allows Ovarian Cancer Diagnosis.

Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer

Utilizing a Pathomics Biomarker to Predict the Effectiveness of Bevacizumab in Ovarian Cancer Treatment

Risk factors for bevacizumab-related proteinuria in patients with colorectal cancer and non-small cell lung cancer

Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images

High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy with Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).

Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study

Identification of novel protein biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity extension analysis

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

Primary application study in early diagnosis of bladder cancer by survivin molecular beacons.

High Levels of D-dimer Correlated with Disease Status and Poor Prognosis of Inoperable Metastatic Colorectal Cancer Patients Treated with Bevacizumab

Predicting prognosis for epithelial ovarian cancer patients receiving bevacizumab treatment with CT-based deep learning

Evaluation of proteinuria monitoring practice patterns and treatment implications in patients with cancer receiving bevacizumab products

Clinical Study on the Safety of Bevacizumab in the Treatment of Patients with Advanced Colorectal Cancer